PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCER
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.254
https://www.valueinhealthjournal.com/article/S1098-3015(18)33554-X/fulltext
Title :
PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33554-X&doi=10.1016/j.jval.2018.09.254
First page :
Section Title :
Open access? :
No
Section Order :
1896